In addition to improvements in both insulin sensitivity and secretion, there is evidence for the benefits of EA in decreasing postprandial hyperglycemia (via inhibition of intestinal α-glucosidase activity) and, to a lesser extent, the modulation of incretin effect. This evidence concerns the gene INS and Hyperglycemia.